MannKind's Revenue Climbs, But Impairment Hits Q3 Net Income

TL;DR

**MNKD's revenue growth is solid, but watch out for those impairment charges and foreign currency hits dragging down the bottom line; the scPharma acquisition is a smart long-term play.**

AI Summary

MannKind Corporation reported a mixed financial performance for the three and nine months ended September 30, 2025. Total revenues increased by 17.2% to $82.1 million for the three months ended September 30, 2025, compared to $70.1 million in the prior year, and by 13.5% to $237.0 million for the nine months ended September 30, 2025, up from $208.7 million. This growth was primarily driven by a 23.0% increase in Afrezza sales to $18.5 million for the quarter and a 24.5% increase in royalties to $33.3 million. However, net income decreased by 30.9% to $8.0 million for the three-month period, down from $11.6 million, largely due to a $6.4 million impairment of available-for-sale investment and a significant increase in foreign currency transaction loss to $7.8 million for the nine-month period. The company also saw a substantial increase in cash and cash equivalents, rising from $46.3 million at December 31, 2024, to $127.4 million at September 30, 2025, partly due to a $75.0 million term loan. A key strategic development was the merger agreement with scPharmaceuticals Inc. on August 24, 2025, which closed on October 7, 2025, adding FUROSCIX to MannKind's product portfolio.

Why It Matters

For investors, MannKind's revenue growth, particularly from Afrezza and Tyvaso DPI royalties, signals strong product performance and market acceptance, which is crucial for a biopharmaceutical company. The acquisition of scPharmaceuticals and its FUROSCIX product diversifies MannKind's portfolio and expands its reach into the chronic heart failure and kidney disease markets, potentially increasing future revenue streams and competitive positioning against rivals in the cardiometabolic space. However, the significant impairment charge and foreign currency losses highlight operational risks that could impact profitability and shareholder value. Employees and customers could benefit from a broader product offering and a more stable company, but the financial volatility warrants close monitoring.

Risk Assessment

Risk Level: medium — The risk level is medium due to a significant impairment loss of $6.4 million on available-for-sale investments for the three months ended September 30, 2025, and a substantial increase in loss on foreign currency transactions to $7.8 million for the nine months ended September 30, 2025, compared to $0.5 million in the prior year. While revenues are growing, these non-operating expenses introduce volatility and impact net income, as evidenced by the 30.9% decrease in net income for the quarter.

Analyst Insight

Investors should closely monitor MannKind's integration of scPharmaceuticals and the commercial performance of FUROSCIX, as this acquisition is a key growth driver. While revenue growth is positive, scrutinize future filings for trends in impairment charges and foreign currency fluctuations, as these can significantly erode profitability despite top-line expansion.

Financial Highlights

revenue

$82.1M

net Income

$8.0M

cash Position

$127.4M

revenue Growth

+17.2%

Revenue Breakdown

Key Numbers

• $82.1M — Total revenues for Q3 2025 (Increased by 17.2% from $70.1M in Q3 2024)
• $237.0M — Total revenues for nine months ended Sep 30, 2025 (Increased by 13.5% from $208.7M in the prior year period)
• $8.0M — Net income for Q3 2025 (Decreased by 30.9% from $11.6M in Q3 2024)
• $21.8M — Net income for nine months ended Sep 30, 2025 (Increased by 8.2% from $20.2M in the prior year period)
• $6.4M — Impairment of available-for-sale investment (Significant expense in Q3 2025, contributing to net income decrease)
• $7.8M — Loss on foreign currency transaction (For nine months ended Sep 30, 2025, up from $0.5M in prior year)
• $127.4M — Cash and cash equivalents (As of Sep 30, 2025, up from $46.3M at Dec 31, 2024)
• $75.0M — Proceeds from term loan (Contributed to increased cash and cash equivalents)
• $18.5M — Afrezza commercial product sales for Q3 2025 (Increased by 23.0% from $15.0M in Q3 2024)
• $33.3M — Royalties for Q3 2025 (Increased by 24.5% from $27.1M in Q3 2024)

Key Players & Entities

• MANNKIND CORP (company) — registrant
• scPharmaceuticals Inc. (company) — acquired company
• FUROSCIX (product) — product acquired from scPharmaceuticals
• Afrezza (product) — commercial product sales
• Tyvaso DPI (product) — royalty-generating product
• United Therapeutics (company) — development and marketing partner for Tyvaso DPI
• FDA (regulator) — U.S. Food and Drug Administration
• Nasdaq Stock Market LLC (company) — exchange where common stock is registered
• SEC (regulator) — Securities and Exchange Commission
• V-Go (product) — wearable insulin delivery device

FAQ

Risk Factors

• Investment Impairment [medium — financial]: The company recorded a $6.4 million impairment of an available-for-sale investment in Q3 2025, negatively impacting net income. This highlights potential volatility in the company's investment portfolio.
• Foreign Currency Fluctuations [medium — financial]: A significant increase in foreign currency transaction loss to $7.8 million for the nine-month period ended September 30, 2025, compared to $0.5 million in the prior year, indicates increased exposure to international market volatility.
• Integration of scPharmaceuticals [high — operational]: The successful integration of scPharmaceuticals Inc. and its product FUROSCIX post-merger (closed October 7, 2025) presents operational and strategic challenges. Failure to integrate effectively could impact future growth and profitability.
• Product Approval and Compliance [high — regulatory]: As a pharmaceutical company, MannKind is subject to stringent regulatory oversight from bodies like the FDA. Delays in approvals, manufacturing compliance issues, or post-market surveillance can significantly impact revenue and operations.
• Competition in Diabetes Market [medium — market]: The diabetes market is highly competitive, with established players and ongoing innovation. MannKind's Afrezza faces competition that could limit market share and pricing power.

Industry Context

The pharmaceutical industry, particularly in the diabetes care segment, is characterized by intense competition, significant R&D investment, and stringent regulatory hurdles. Companies like MannKind must navigate patent cliffs, generic competition, and evolving treatment paradigms. The recent merger with scPharmaceuticals indicates a strategy to diversify and strengthen its market position through product acquisition.

Regulatory Implications

MannKind operates under the strict oversight of regulatory bodies such as the FDA. Compliance with manufacturing standards, clinical trial protocols, and post-market surveillance is critical. Any adverse findings or delays in regulatory approvals for existing or new products could materially impact financial performance and market access.

What Investors Should Do

1. Monitor integration progress of scPharmaceuticals.
2. Analyze the impact of foreign currency fluctuations.
3. Evaluate the sustainability of revenue growth drivers.

Key Dates

• 2025-08-24: Merger Agreement with scPharmaceuticals Inc. — Marks a significant strategic move to expand the product portfolio with FUROSCIX.
• 2025-10-07: Merger with scPharmaceuticals Inc. closed — Officially integrated FUROSCIX into MannKind's product offerings, creating potential for synergistic growth.

Glossary

Available-for-sale investment

Investments that are not classified as held-to-maturity or trading securities. They are reported at fair value, with unrealized gains and losses included in other comprehensive income. (A $6.4 million impairment of such an investment impacted Q3 2025 net income.)

Foreign currency transaction loss

Losses incurred when a company's transactions denominated in a foreign currency are settled at a less favorable exchange rate than the rate at which they were recorded. (A significant increase in this loss ($7.8M for nine months) negatively affected the company's profitability.)

Term loan

A loan from a bank or other lender that has a specified repayment schedule and a fixed or floating interest rate, typically used for specific business purposes. (A $75.0 million term loan contributed to the substantial increase in cash and cash equivalents.)

Year-Over-Year Comparison

For the three months ended September 30, 2025, MannKind Corporation saw a notable 17.2% increase in total revenues to $82.1 million, driven by strong Afrezza sales and royalties. However, net income declined by 30.9% to $8.0 million, primarily due to a $6.4 million investment impairment and increased foreign currency losses. Cash reserves significantly improved, bolstered by a $75.0 million term loan, reaching $127.4 million from $46.3 million at year-end 2024.

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share MNKD The Nasdaq Stock Mar

Filing Documents

• mnkd-20250930.htm (10-Q) — 4094KB
• mnkd-ex10_1.htm (EX-10.1) — 79KB
• mnkd-ex10_2.htm (EX-10.2) — 1612KB
• mnkd-ex31_1.htm (EX-31.1) — 15KB
• mnkd-ex31_2.htm (EX-31.2) — 15KB
• mnkd-ex32_1.htm (EX-32.1) — 11KB
• mnkd-ex32_2.htm (EX-32.2) — 11KB
• 0001193125-25-265813.txt ( ) — 19670KB
• mnkd-20250930.xsd (EX-101.SCH) — 2627KB
• mnkd-20250930_htm.xml (XML) — 3586KB

: FINANCIAL INFORMATION

PART I: FINANCIAL INFORMATION 2

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) 2 Condensed Consolidated Statements of Operations: Three and nine months ended September 30, 2025 and 2024 2 Condensed Consolidated Statements of Comprehensive Income : Three and nine months ended September 30, 2025 and 2024 3 Condensed Consolidated Balance Sheets: September 30, 2025 and December 31, 2024 4 Condensed Consolidated Statements of Stockholders' Deficit: Three and nine months ended September 30, 2025 and 2024 5 Condensed Consolidated Statements of Cash Flows: Nine months ended September 30, 2025 and 2024 6 Notes to Condensed Consolidated Financial Statements 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 38

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 47

Controls and Procedures

Item 4. Controls and Procedures 47

: OTHER INFORMATION

PART II: OTHER INFORMATION 48

Legal Proceedings

Item 1. Legal Proceedings 48

Risk Factors

Item 1A. Risk Factors 48

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 79

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 79

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 79

Other Information

Item 5. Other Information 79

Exhibits

Item 6. Exhibits 80

SIGNATURES

SIGNATURES 82 1 PART 1: FINANCIA L INFORMATION

FINANCI AL STATEMENTS

ITEM 1. FINANCI AL STATEMENTS MANNKIND CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDAT ED STATEMENTS OF OPERATIONS (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 (In thousands except per share data) Revenues: Commercial product sales $ 22,305 $ 19,728 $ 63,732 $ 59,272 Collaborations and services 26,506 23,268 78,727 74,130 Royalties 33,319 27,083 94,552 75,326 Total revenues 82,130 70,079 237,011 208,728 Expenses: Cost of goods sold – commercial 4,498 3,197 12,873 12,621 Cost of revenue – collaborations and services 15,705 14,826 45,414 44,377 Research and development 14,063 12,926 38,760 34,755 Selling, general and administrative 29,088 23,916 85,724 70,357 (Gain) loss on foreign currency transaction ( 120 ) 2,454 7,752 526 Total expenses 63,234 57,319 190,523 162,636 Income from operations 18,896 12,760 46,488 46,092 Other income (expense): Interest income, net 2,628 3,179 6,416 9,790 Interest expense ( 1,364 ) ( 1,801 ) ( 6,294 ) ( 10,419 ) Interest expense on liability for sale of future royalties ( 3,514 ) ( 4,089 ) ( 10,564 ) ( 12,720 ) Interest expense on financing liability ( 2,456 ) ( 2,470 ) ( 7,299 ) ( 7,361 ) Impairment of available-for-sale investment ( 6,409 ) — ( 6,409 ) ( 1,550 ) Other income — 32 — 32 Gain on bargain purchase — 5,259 — 5,259 Loss on settlement of debt — — — ( 7,050 ) Total other (expense) income ( 11,115 ) 110 ( 24,150 ) ( 24,019 ) Income before income tax (benefit) expense 7,781 12,870 22,338 22,073 Income tax (benefit) expense ( 204 ) 1,320 527 1,907 Net income $ 7,985 $ 11,550 $ 21,811 $ 20,166 Net income per share – basic $ 0.03 $ 0.04 $ 0.07 $ 0.07

View Full Filing

View this 10-Q filing on SEC EDGAR